GlobalData on MSN17h
Ractigen’s RAG-01 shows potential in treating non-muscle invasive bladder cancer
The company’s Phase I trial found that patients remained disease free after three months utilising the lowest doses of RAG-01.
PharmiWeb20h
New study results reinforce Tagrisso as the backbone therapy for EGFR-mutated lung cancer across stages and settings
New study results presented at the European Lung Cancer Congress (ELCC) 2025, 26 to 29 March, demonstrate the role of AstraZeneca’s Tagrisso (osimertinib), as monotherapy and as the backbone for novel ...
Fidelity International12h
AstraZeneca PLC (AZN)
AstraZeneca PLC belongs to the healthcare sector. The company develops and markets pharmaceutical products for various therapeutic classes such as gastrointestinal, cardiovascular, respiratory, cancer ...